key: cord-0872959-hiogtphd
authors: Joyce, Michael G.; King, Hannah A. D.; Naouar, Ines Elakhal; Ahmed, Aslaa; Peachman, Kristina K.; Cincotta, Camila Macedo; Subra, Caroline; Chen, Rita E.; Thomas, Paul V.; Chen, Wei-Hung; Sankhala, Rajeshwer S.; Hajduczki, Agnes; Martinez, Elizabeth J.; Peterson, Caroline E.; Chang, William C.; Choe, Misook; Smith, Clayton; Lee, Parker J.; Headley, Jarrett A.; Taddese, Mekdi G.; Elyard, Hanne A.; Cook, Anthony; Anderson, Alexander; McGuckin-Wuertz, Kathryn; Dong, Ming; Swafford, Isabella; Case, James B.; Currier, Jeffrey R.; Lal, Kerri G.; O’Connell, Robert J.; Molnar, Sebastian; Nair, Manoj S.; Dussupt, Vincent; Daye, Sharon P.; Zeng, Xiankun; Barkei, Erica K.; Staples, Hilary M.; Alfson, Kendra; Carrion, Ricardo; Krebs, Shelly J.; Paquin-Proulx, Dominic; Karasavva, Nicos; Polonis, Victoria R.; Jagodzinski, Linda L.; Amare, Mihret F.; Vasan, Sandhya; Scott, Paul T.; Huang, Yaoxing; Ho, David D.; de Val, Natalia; Diamond, Michael S.; Lewis, Mark G.; Rao, Mangala; Matyas, Gary R.; Gromowski, Gregory D.; Peel, Sheila A.; Michael, Nelson L.; Bolton, Diane L.; Modjarrad, Kayvon
title: Efficacy of a Broadly Neutralizing SARS-CoV-2 Ferritin Nanoparticle Vaccine in Nonhuman Primates
date: 2021-03-25
journal: bioRxiv
DOI: 10.1101/2021.03.24.436523
sha: 305cc55486522f480d00cbe92667f0e46e9b8922
doc_id: 872959
cord_uid: hiogtphd

The emergence of novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants stresses the continued need for next-generation vaccines that confer broad protection against coronavirus disease 2019 (COVID-19). We developed and evaluated an adjuvanted SARS-CoV-2 Spike Ferritin Nanoparticle (SpFN) vaccine in nonhuman primates (NHPs). High-dose (50 µg) SpFN vaccine, given twice within a 28 day interval, induced a Th1-biased CD4 T cell helper response and a peak neutralizing antibody geometric mean titer of 52,773 against wild-type virus, with activity against SARS-CoV-1 and minimal decrement against variants of concern. Vaccinated animals mounted an anamnestic response upon high-dose SARS-CoV-2 respiratory challenge that translated into rapid elimination of replicating virus in their upper and lower airways and lung parenchyma. SpFN’s potent and broad immunogenicity profile and resulting efficacy in NHPs supports its utility as a candidate platform for SARS-like betacoronaviruses. One-Sentence Summary A SARS-CoV-2 Spike protein ferritin nanoparticle vaccine, co-formulated with a liposomal adjuvant, elicits broad neutralizing antibody responses that exceed those observed for other major vaccines and rapidly protects against respiratory infection and disease in the upper and lower airways and lung tissue of nonhuman primates.

and efficacy, but provide broader coverage against a wide range of circulating variants and 66 evolving strains, as well as novel species that may arise from zoonotic reservoirs in the future. 67

Self-assembling protein nanoparticle vaccines offer the advantage of multivalent antigen 68 presentation, a property previously shown to augment immunogenicity over monovalent 69 immunogens (6-8). Ferritin is a naturally occurring, ubiquitous, iron-carrying protein that self-70 oligomerizes into a 24-unit spherical particle (9). The three-fold axis symmetry of the resulting 71 polymer makes it conducive to conjugation and antigen display of trimeric glycoproteins, such as 72 SARS-CoV-2 Spike (S). Ferritin has been evaluated as a vaccine platform for several pathogens 73 (10-12)-most notably influenza, for which it has demonstrated immune potency and breadth (13, 74 14) . As such, ferritin vaccines have advanced to phase 1 clinical trials as a strategy to target 75 multiple influenza strains (15, 16) . 76

The prefusion-stabilized form of S is the basis for most major SARS-CoV-2 vaccine 77 candidates (17, 18). Although a correlate of protection from Covid-19 has not been conclusively 78 defined, there is mounting evidence that neutralizing, and some fraction of non-neutralizing, 79

antibodies against S are necessary, if not sufficient, to confer protective immunity (19, 20) . The virus neutralization activity mirrored group differences seen in the pseudovirus assay, but at 124 somewhat lower values (Fig. 1C) . 125

We performed functional assessments of antibody responses by measuring the ability of 126 sera to inhibit binding of RBD to the ACE2 receptor. Binding inhibition in the 5 and 50 µg 127 vaccinated animals exceeded unvaccinated controls by a factor of 224 and 998, respectively (Fig.  128   1D ). ACE2 competition in the single 50 µg dose group was 291 times higher than controls. We 

The character of the helper CD4+ T cell (Th) response is important for respiratory virus vaccine 147 development, given the theoretical concern and precedent for vaccine-associated enhanced 148 respiratory disease and its association with a Th2-biased response (28). We focused our 149 assessment of cell-mediated immunity on canonical cytokines expressed by Th1 (interferon-150 gamma (IFN-γ), tumor necrosis factor (TNF), interleukin 2 (IL-2)) and Th2 (IL-4, IL-13) CD4 T 151 cells. Robust Th1 responses were observed 4 weeks after second vaccination in all vaccinated 152 groups, except one animal in the 50 µg single-dose group ( Fig. 2A) . Th1 responses were 153 polyfunctional and variable but consistently high at week 8, ranging from 0.2% to 17%. Th2 and 154 CD8+ T cell responses were minimal or undetectable (Fig. 2B, fig. S6A ), though Th1 and Th2 155 responses correlated strongly (r=0.72, p<0.0001). We expanded the assessment of the breadth of SpFN immunogenicity by interrogating the 217 neutralizing and non-neutralizing antibody and cellular immune responses against SARS-CoV-1, 218

Binding of vaccinee sera to SARS-CoV-1 RBD, as measured by biolayer interferometry, was 219 absent in controls but was relatively potent in vaccinated animals-binding at half the strength of 220 that observed to SARS-CoV-2 RBD ( fig. S3, S4, Fig. 6A ). Antibody-dependent cellular 221 phagocytosis (ADCP) activity also increased remarkably in all vaccine groups, reaching a score 222 that was 100-fold higher two-weeks after last 50 µg SpFN vaccination than baseline or 223 unvaccinated controls (Fig. 6B ). Two vaccinations with high-dose SpFN also yielded significant 224 plaque reduction neutralizing activity against authentic SARS-CoV-1 with a reciprocal ID50 225 GMT of 390 (Fig. 6C ) that was significantly above background (p=0.007). An orthogonal 226 pseudovirus neutralization assay exhibited significant background activity in PBS controls. We 227 minimized background by analyzing neutralization activity at a 90% inhibitory dilution (ID90) 228

and found that two doses of 50 µg SpFN induced neutralizing activity against SARS-CoV-1 that 229 was 6-fold higher (GMT 667) than controls (Fig. 6D ). CD4+ T cell responses to SARS-CoV-1 S 230 peptides, though lower in absolute percentage than to SARS-CoV-2, were still robust and strongly 231 Th1-biased (Fig. 6E,F) . The CD8+ T cell response, in contrast, was minimal ( fig. S9A-C) . In 232 aggregate, the immunogenicity profile of SpFN to SARS-CoV-1, though lower in magnitude, 233 recapitulated the quality of response observed to SARS-CoV-2. 234 235

The recent success in the rapid development of safe and efficacious SARS-CoV-2 vaccines has 237 been tempered by the emergence of virus variants to which vaccine-induced immunity has shown 238 diminished potency or efficacy (30-34). There remains a need, therefore, for next-generation 239 vaccines that target the broadening antigenic diversity of SARS-CoV-2 and related coronaviruses. SpFN vaccine, we recapitulate or surpass the protective efficacy against SARS-CoV-2 infection 246 seen in other studies, but with a greater reduction in replicating virus against a more potent 247 challenge than has been used previously. Additionally, we demonstrate that SpFN elicited 248 antibodies neutralize SARS-CoV-2 ten times more potently than most vaccines and that 249 neutralizing activity is either higher or equivalent against two major VOCs (B.1.1.7, B.1.351) in 250 an authentic virus neutralization assay and equivalent or mildly diminished in a pseudovirus 251 neutralization assay. Finally, SpFN demonstrates neutralization capacity of SARS-CoV-1-a 252 separate species that has 26% and 36% sequence divergence in the S protein and S1 subunit, 253 respectively (40)-above thresholds associated with protection in animals studies (41, 42) . 254 SARS-CoV-2 vaccine efficacy studies in NHPs generally compare elicited antibody 255 responses to those from recovered Covid-19 patients. We found neutralizing activity in the two-256 dose 50 µg SpFN group to be ten-fold higher than that in recovering patients. However, given the 257 preponderance of animal data generated across the vaccine landscape and the lack of 258 standardization across convalescent serum panels, we deemed it more relevant to focus 259 immunogenicity comparisons to published data from other vaccines evaluated in NHP studies. 260

We found that SARS-CoV-2 antibody responses in animals vaccinated with high-dose SpFN were 261 significantly higher than those generated by high doses of leading genetic vaccines (35, 39). That 

Advisory Committee on Immunization Practices

Recommended Immunization Schedule for Adults Aged 19 Years or Older -United 318

SARS-CoV-2 Viral Variants-Tackling a 320

Increased Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 to 322

The operational impact of deploying SARS-CoV-2 vaccines in countries 324 of the WHO African Region. medRxiv

Framework for Equitable Allocation of COVID-19 Vaccine

Self-assembling influenza nanoparticle vaccines drive extended 328 germinal center activity and memory B cell maturation

Multifaceted Effects of Antigen Valency on B Cell Response Composition 330 and Differentiation In Vivo